Even though the European Medicines Agency (EMA) has suspended publication of clinical data through Policy 0070 due to its Brexit business continuity plan, EMA posted a Policy 0070 external guidance update on November 11, 2018. Revision 4 is now in effect. Policy 0070 External Guidance Update – Major Changes Several major changes are noted in this … Continued
https://www.certara.com/blog/policy-0070-guidance-update/Policy 0070― published by the European Medical Agency (EMA) in October 2014― has made the world of regulatory writing a more complicated place. The policy requires specified submission documents to be made public for all marketing authorization applications (MAA’s) submitted as of January 1, 2015 and for all indication extensions and line extensions submitted as … Continued
https://www.certara.com/blog/streamline-your-approach-to-ema-policy-0070/In many ways, the strategic planning required to comply with EMA Policy 0070―a requirement to publish anonymized versions of clinical study reports (CSRs) and other submission documents―is similar to a secret agent’s mission: sponsors must keep the identities of people named or referred to in those documents top-secret while maintaining the document’s clinical utility. In … Continued
https://www.certara.com/blog/ema-policy-0070-compliance-tips-from-james-bond/Background In 2018, the Food and Drug Administration (FDA) launched a pilot to test the capability of publicly posting summaries of the safety and efficacy information that is used to make drug approval decisions. This followed suit with the European Medicine Agency’s (EMA) Policy 0070 that launched in 2015 and Health Canada’s (HC) Clinical Information … Continued
https://www.certara.com/blog/fda-seeking-feedback-on-drug-approval-transparency-and-disclosure-efforts/Speaker Lora Killian provides insight on how EMA Policy 0070 will affect your organization and how to facilitate compliance, addressing many critical transparency and disclosure issues.
https://www.certara.com/on-demand-webinar/navigating-ema-policy-0070-how-do-we-ensure-compliance/Under European Union Clinical Trial Regulation 536/2014 (EU-CTR), replacing the EU Clinical Trial Directive (Directive 2001/20/EC), drug developers must now anonymize or redact clinical trial documents at the same time they are preparing them for regulatory submission (read more about the redaction process in this blog). This makes complying with transparency and disclosure requirements necessary … Continued
https://www.certara.com/blog/eu-ctr-challenges-drug-developers-face/Choosing the right technology and services vendor to support your organization’s transparency and disclosure (T&D) requirements to health authorities is a critical decision. The vendor selection process varies greatly. Some organizations have rigorous prescribed procedures, while others boast a less formal, less structured process. You need to select a vendor who will help to maintain … Continued
https://www.certara.com/blog/checklist-clinical-trial-transparency-disclosure-vendors/The European Commission published a notice to stakeholders on September 6, reminding pharmaceutical companies of some unexpected impacts of Brexit in multiple areas, including the submission of clinical trial information to EudraCT. The submission of certain clinical trial information to the European Union (EU) database is a provision of an EU law which will no … Continued
https://www.certara.com/blog/brexit-impact-on-eudract/Over seven years ago, the Management Board of the European Medicines Agency (EMA) adopted Policy 0070, a requirement to publish anonymized versions of clinical study reports (CSRs) and other regulatory submission documents. In December 2018, EMA enacted their business continuity plan, which meant publication of clinical data was put on hold. A limited return of … Continued
https://www.certara.com/blog/european-canadian-partnership-streamlines-clinical-data-anonymization-redaction/Did you know that you’re likely using artificial intelligence (AI) in your everyday life? For example, the digital music service, Spotify, creates “mood-based” playlists that are curated to users’ musical preferences. Spotify generates these customized play lists using a machine learning algorithm that has learned your unique musical preferences based on your previous interactions with … Continued
https://www.certara.com/blog/how-ai-tech-is-changing-regulatory-writing/
